8-K: Tempest Therapeutics Announces Positive Survival Data for Amezalpat in Liver Cancer Study

Tempest Therapeutics reports a six-month improvement in median overall survival for its drug amezalpat in a first-line liver cancer study.

Summary

• Tempest Therapeutics has released new data from a Phase 1b/2 clinical study of amezalpat (TPST-1120) in combination with atezolizumab and bevacizumab for first-line treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
• The study showed a six-month improvement in median overall survival (OS) for the amezalpat arm compared to the control arm.
• The median OS was 21 months in the amezalpat arm versus 15 months in the control arm.
• The hazard ratio (HR) for OS was 0.65, which is consistent with the 0.59 observed in the primary analysis 10 months earlier.
• 50% of patients in the amezalpat arm remained in survival follow-up, compared to 30% in the control arm.
• The study included 40 patients in the amezalpat arm and 30 in the control arm.
• Earlier data from April 20, 2023, showed a confirmed objective response rate (cORR) of 30% for the amezalpat arm versus 13.3% for the control arm.
• Patients with b-catenin activating mutations showed a cORR of 43% and a disease control rate (DCR) of 100% in the amezalpat arm.
• The amezalpat arm showed consistent activity across both PD-L1 positive and PD-L1 negative tumors.

Sentiment

Score: 9

Explanation: The document presents very positive clinical trial results with a significant improvement in overall survival and a consistent hazard ratio. The company is also actively raising capital, which is a positive sign for future development. The sentiment is very strong.

Positives

• The six-month improvement in median overall survival is a significant positive outcome.
• The consistent hazard ratio of 0.65 indicates a stable and positive treatment effect.
• The high percentage of patients remaining in survival follow-up in the amezalpat arm suggests a durable benefit.
• The drug showed activity across different patient subgroups, including those with b-catenin mutations and both PD-L1 positive and negative tumors.
• Amezalpat continues to demonstrate a manageable safety profile.

Negatives

• The study is a Phase 1b/2 trial, and further Phase 3 trials are needed to confirm these results.
• The control arm also includes atezolizumab and bevacizumab, which are standard of care treatments, so the improvement is relative to an already effective treatment.

Risks

• The success of amezalpat in a Phase 3 trial is not guaranteed.
• Regulatory approval is not assured, even with positive Phase 3 results.
• The competitive landscape for HCC treatments is evolving, and new therapies may emerge.
• The company is reliant on Roche for the management of the study operations.

Future Outlook

The company believes the new data puts amezalpat in a strong position for a successful pivotal Phase 3 trial. The company will continue to develop amezalpat and explore its potential in treating various cancers.

Management Comments

• Stephen Brady, president and chief executive officer of Tempest, stated that they are thrilled by the new survival data.
• He believes the results put amezalpat in a strong position for a successful pivotal Phase 3 trial.

Industry Context

The announcement is significant in the context of the rising incidence and mortality of HCC, which is projected to become the third leading cause of cancer death by 2030. The positive results for amezalpat suggest a potential new treatment option for this aggressive cancer.

Comparison to Industry Standards

• The current standard of care for first-line HCC treatment includes atezolizumab and bevacizumab, which are used in the control arm of this study.
• The six-month improvement in median OS with amezalpat is a notable advancement over the existing standard of care.
• Other companies such as Roche are also developing treatments for HCC, but the specific results of this study are unique to Tempest's amezalpat.
• The hazard ratio of 0.65 is competitive with other experimental therapies in this space.
• The confirmed objective response rate of 30% in the amezalpat arm is also a positive indicator compared to other treatments.

Stakeholder Impact

• Shareholders will likely react positively to the strong clinical trial results and the potential for a successful Phase 3 trial.
• Patients with HCC may benefit from a new treatment option if amezalpat is approved.
• Employees of Tempest Therapeutics may be motivated by the positive progress of the company's lead drug candidate.
• The company's collaboration with Roche may be strengthened by the positive data.

Next Steps

• The company plans to advance amezalpat into a pivotal Phase 3 trial.
• The company will continue to monitor the patients in the ongoing study.
• The company will host a webcast conference call to discuss the new data.

Key Dates

Keywords

amezalpat, TPST-1120, hepatocellular carcinoma, HCC, overall survival, OS, cancer, oncology, clinical trial, PPAR antagonist, atezolizumab, bevacizumab